TABLE 2.

Patient outcomes

Variable	No. of patients positive with the four-drug regimen (n = 91)	No. of patients positive with the three-drug regimen (n = 89)	P value
Relapse to end of follow-up period
Culture confirmed	9 (9.9%)	7 (7.9%)	0.63
Clinical	9 (9.9%)	7 (7.9%)	0.63
Overall	18 (19.8%)	14 (15.7%)	0.48
Died	10 (11.0%)	12 (13.5%)	0.61
Attributable to primary or relapse infection	9 (9.9%)	9 (10.1%)	0.96
Other cause	0	3a (3.4%)	0.12
Unknown	1 (1.1%)	0	1.00
Switch in treatment	48 (52.7%)	22 (24.7%)	<0.001
Due to adverse drug event	33 (36.3%)	17 (19.1%)	0.01
Due to other reasons	15 (16.5%)	5 (5.6%)	0.02
Follow-up of less than 3 months	14 (15.4%)	22 (24.7%)	0.12
Duration of allocated regimen, median (IQR)b	3.7 (1.9-18.1)	10.1 (2.3-19.6)	0.046
≤12 weeks	43 (47.3%)	47 (52.8%)	0.46
12 to 20 weeks	36 (39.6%)	28 (31.5%)	0.26
>20 weeks	12 (13.2%)	14 (15.7%)	0.63
Duration of total oral treatment, median (IQR)	19 (13.3-20.3)	17 (4.0-20.6)	0.17
≤12 weeks	23 (25.3%)	33 (37.1%)	0.09
12 to 20 weeks	41 (45.1%)	32 (36.0%)	0.21
>20 weeks	27 (29.7%)	24 (27.0%)	0.69

^aDeath due to human immunodeficiency virus coinfection (1), heart disease (1), and non-melioidosis postoperative wound infection (1).

^bIQR, interquartile range.